

MEMORANDUM

To: All Wards and Departments, NHS Lothian
From: Ommar Ahmed, Clinical Pharmacy Lead, RIE
Date: 18 September 2025
Subject: **Dalteparin to Enoxaparin switch**

Dalteparin has been the medication of choice for parenteral anticoagulation in NHS Lothian since 2010. A new national contract for anticoagulants has been implemented since 1st May 2025. Contract prices for dalteparin has considerably increased and will be a significant cost pressure for all clinical areas across NHS Lothian.

Based on the current contract, Inhixa® brand of enoxaparin is the most cost-effective parenteral anticoagulant. A switch from dalteparin to enoxaparin has been approved by NHS Lothian Acute services. This switch to enoxaparin will not only avoid additional cost but in fact will result in considerable savings for the health board.

Paediatrics team will continue to use dalteparin in children for thromboprophylaxis due to dosing frequency. However, enoxaparin will be used for treatment of Venous Thromboembolism.

Lothian antithrombotic guide along with speciality specific protocols are being updated. It will be published on Intranet from 29th September 2025. Staff training across clinical areas is planned to commence from next week.

Important dates to remember:

Staff training commences	22 nd September 2025
Grand Round (Launch of new guideline)	1 st October 2025
Switch from dalteparin to enoxaparin	7th October 2025

Further information with regards to a plan for switching patients from dalteparin to enoxaparin will be shared in the week commencing 29th September.